Cell lines and treatments

Four CML cell lines -K562, KBM-5, MEG01 and BV173 -were used. The P6 (BALB/c3T3 mouse fibroblasts overexpressing human IGF-IR) and R
Ϫ (mouse fibroblast 3T3-like cells with a targeted ablation of Igf1r gene) cell lines were a generous gift from Dr. R. Baserga (Philadelphia, PA, USA) and were used as positive and negative controls for the expression of IGF-IR, respectively [26]. BaF3 cells expressing wild-type (WT) p210 BCR-ABL, BCR-ABL mutants or empty vector were kindly provided by Dr. C. Sawyers (New York, NY, USA)
. The Cell viability, proliferation, apoptosis, cell cycle and colony formation in soft agar assays (Fig. 1D ). In addition, tyrosine kinase activity assay showed the KBM-5 and MEG01 cell lines to possess significantly lower tyrosine kinase activity (Fig. 1E ).
Cell viability was evaluated by exclusion of staining by trypan blue dye. Apoptosis was examined by using flow cytometry (FACscan, BD Pharmingen, San Jose, CA, USA) after staining the cells with annexin V-FITC and propidium iodide (PI) (BD Pharmingen). Analysis of the cell cycle was performed with a commercially available kit (CycleTEST PLUS
DNA
The expression of IGF-IR was also studied in a tissue microarray that included primary bone marrow specimens from CML patients at different stages of the disease (Fig. 2A). Only 3 of 10 (30%) and 2 of 8 (25%) of CP and AP CML patients expressed IGF-IR, respectively. Nonetheless, the frequency of IGF-IR expression increased to 11 of 15 (73%) of CML patients during the advanced BP. Increased expression levels of IGF-IR with the progression of CML was further supported by quantitative real-time PCR that demonstrated significantly higher levels of IGF-IR mRNA in the majority of BP patients compared with CP and AP patients (Fig. 2B).
Selective or specific antagonism of IGF-IR induces negative biological effects in CML cell lines
PPP, a selective inhibitor of IGF-IR, decreased the viability of CML cell lines. This effect was both concentration and time dependent and was more pronounced in the cell lines KBM-5 and MEG01
when compared with K562 and BV173 (Fig. 3A) (Fig. 3A) . The human skin fibroblast cells AG01523 were used as a negative control for the effect of the treatment with PPP [14] . (Fig. 3C ). Apoptosis and cell cycle arrest were also morphologically documented after staining of the cells with Giemsa (Fig. 3D) 
Also, PPP induced concentration-and time-dependent increase in apoptotic cell death in CML cell lines. Apoptosis was demonstrated by flow cytometric analysis of annexin V binding (Fig. 3B). Cells were considered apoptotic when stained for annexin V only or when stained simultaneously for annexin V and
Fig. 1 Expression of IGF-IR in CML cell lines. (A) Immunohistochemical staining shows strong and universal expression of IGF-IR in four CML cell lines including K562, KBM-5, MEG01 and BV173. (B) Western blotting confirms the expression of IGF-IR protein in all of the CML cell lines. The K562 cell line demonstrates a higher level of IGF-IR protein compared with the other three cell lines. ␤-Actin confirms equal loading. (C) RT-PCR shows the expression of IGF-IR mRNA in CML cell lines. Similar to IGF-IR protein levels, K562 cells appear to express the highest level of IGF-IR
PI. Similar to the changes in cell viability, inhibition of IGF-IR by PPP was associated with more apoptotic death in the two cell lines KBM-5 and MEG01. Furthermore, PPP induced G2/M-phase cell cycle arrest in the four cell liens included in the study
Blockade of IGF-IR decreases the viability of imatinib-resistant p210 BCR-ABL-expressing cell lines or primary neoplastic cells
To test the effect of inhibition of IGF-IR on imatinib-resistant p210 BCR-ABL-expressing cells, we employed three different approaches. In the first, we used BaF3 cells permanently transfected with WT p210 BCR-ABL or one of its mutants BCR-ABL E255K
or BCR-ABL T315I that are known to be resistant to imatinib. As shown in Fig. 5A (Fig. 5D) . (Fig. 5F ). [20, 21] . [23, 32, 33] . Furthermore, imatinib is much less effective when patients evolve into the more aggressive BP stage where sometimes they develop BCR-ABL gene amplifications [23] . [7] [8] [9] [10] [11] 36] . Despite the stimulatory effects that IGF-IR exerts on haematopoietic cells [12, 37, 38] 
Lastly, we examined the effect of inhibition of IGF-IR by PPP on primary neoplastic cells collected from five imatinib-resistant CML patients (two in CP and three in BP). PPP efficiently induced
time-and concentration-dependent decrease in the viability of these cells (Fig. 5E). The decrease in the viability of these cells could be explained at least partially by occurrence of apoptotic cell death as demonstrated by cell shrinkage, nuclear condensation, nuclear fragmentation and cytoplasmic vacuolization
Effects of selective or specific down-regulation of IGF-IR on IGF-IR, BCR-ABL and downstream target molecules
To this end we sought to explore a biochemical explanation for the negative effects observed in CML cells after blockade of IGF-IR signalling. We first tested the effects of PPP on IGF-IR and BCR-ABL tyrosine kinases. Whereas PPP decreased the tyrosine kinase activity of IGF-IR in a concentration-dependent fashion in K562 and KBM-5 cell lines, it did not induce a similar effect on BCR-ABL (Fig. 6A). In addition, Western blotting and co-immunoprecipitation studies (the KBM-5 cell line is depicted as a representative example) showed that PPP decreased the levels of tyrosine phosphorylated IGF-IR in a concentration-dependent manner (Fig. 6B). Of important note is that PPP did not reduce the tyrosine phosphorylation levels of BCR-ABL (Fig. 6B). The decrease in IGF-IR tyrosine kinase activity and pIGF-IR levels was associated with down-regulation of activated/phosphorylated Akt and STAT5. PPP also caused concentration-dependent decreases in Bcl-2, Bcl-XL and caspase-3, which is consistent with apoptotic cell death. Finally, inhibition of IGF-IR induced significant alterations in cell cycle regulatory proteins. Specifically, PPP induced up-regulation of cyclin B1, and simultaneous down-regulation of cyclin E and pCdc2. Changes were not seen in Cdc2 or p16. Collectively, these results are consistent with G2/M-phase cell cycle arrest. We also confirmed some of the molecular effects of PPP by using siRNA to specifically down-regulate IGF-IR. Transfection of the KBM-5 cell line with IGF-IR siRNA decreased IGF-IR protein level, whereas BCR-ABL and pBCR-ABL protein levels remained unaltered (Fig. 6C). Similar to the effects observed with PPP, down-regulation of IGF-IR by siRNA was associated with a notable decrease in pAkt and pSTAT5 proteins (Fig. 6C).
Discussion
CML is the most common form of chronic myeloproliferative diseases and is characterized by the BCR-ABL chimeric protein that
Fig. 4 Specific blockade of IGF-IR decreases cell viability and induces apoptosis in CML cell lines. (A) IGF-IR siRNA decreases the viability of K562, KBM-5 and BV173 cell lines. The decrease in cell viability is time-dependent and becomes more pronounced at 48 hrs after transfection of the cells. At 24 hrs, the KBM-5 cell line appears to be more sensitive to the effects of IGF-IR siRNA when compared with K562 and BV173. *: P Ͻ 0.05 and †: P Ͻ 0.001 versus control untreated cells and ‡: P Ͻ 0.05 versus IGF-IR siRNA (24 hrs). Comparing the collective effect of IGF-IR siRNA on decreasing the viability of the K562 and BV173 cell lines versus KBM-5 demonstrated that P ϭ 0.0002. (B) IGF-IR siRNA increases apoptotic cell death in K562, KBM-5 and BV173 cell lines. The effect of IGF-IR siRNA is pronounced in the KBM-5 cell line at 24 hrs after transfection and
Fig. 5 Inhibition of IGF-IR decreases the viability of imatinib-resistant p210 BCR-ABL-expressing cells. (A) Western blotting shows the expression of IGF-IR, pIGF-IR, WT p210 BCR-ABL, BCR-ABL E255K or BCR-ABL T315I in BaF3 cells. BaF3 cells transfected with empty vector lack the expression of BCR-ABL.
␤-Actin confirms equal loading of the proteins. (B) Only BaF3 cells transfected with WT p210 BCR-ABL demonstrate time-dependent decrease in cell viability after treatment with imatinib (5.0 M). In contrast, BaF3 cells transfected with BCR-ABL mutants or empty vector are completely resistant to imatinib treatment. *: P Ͻ 0.001 compared with control untreated cells and †: P Ͻ 0.001 compared with imatinib (5.0 M; 24 hrs). (C) Targeting IGF-IR by PPP induces concentration-and time-dependent decrease in the viability of BaF3 cells transfected with WT BCR-ABL or the BCR-ABL
Nonetheless, this therapeutic approach is not always effective because some patients develop BCR-ABL gene mutations that render them resistant to imatinib
Recent studies in mice demonstrated that targeting multiple kinases is more effective in improving treatment of BCR-ABL-expressing leukaemia [34]. In addition, considering the steady increase in the number of CML patients who develop resistance to imatinib, identifying BCR-ABL-independent new therapeutic pathways to be utilized for the treatment of these patients is highly needed [35]. Signalling through the IGF-IR tyrosine kinase has recently become a major focus of cancer research and most of this research has been related to solid tumours
